Vincristine/Irinotecan Upfront Window Treatment of High-risk Hepatoblastoma: A Report from the Children’s Oncology Group (COG) AHEP0731 Study Committee

PURPOSE: The identification of new therapies for high-risk (HR) hepatoblastoma (HB) is challenging. Children’s Oncology Group Study AHEP0731 included a HR stratum to explore the efficacy of novel agents. We report the response rate to vincristine/irinotecan and the outcome of high-risk HB patients....

詳細記述

保存先:
書誌詳細
出版年:Cancer
主要な著者: Katzenstein, HM, Furman, WL, Malogolowkin, MH, Krailo, MD, McCarville, MB, Towbin, AJ, Tiao, GM, Finegold, M, Ranganathan, S, Dunn, SP, Langham, MR, McGahren, ED, Rodriguez-Galindo, C, Meyers, RL
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665173/
https://ncbi.nlm.nih.gov/pubmed/28211941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30591
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料